Axsome Therapeutics, Inc. announced the appointment of Randall Kaye, M.D. as Chief Medical Officer, effective immediately. Dr. Kaye will oversee the development of the company's pipeline, including its two late-stage clinical programs, AXS-02 and AXS-05. Prior to joining Axsome, Dr. Kaye was Chief Medical Officer, and Senior Vice President, Clinical Research and Medical Affairs, at Avanir Pharmaceuticals.

While at Avanir, Dr. Kaye provided leadership and vision to the clinical, regulatory and medical affairs areas.